Oxcarbazepine in Adults with Developmental Disabilities.
Abstract number :
2.269
Submission category :
Year :
2001
Submission ID :
307
Source :
www.aesnet.org
Presentation date :
12/1/2001 12:00:00 AM
Published date :
Dec 1, 2001, 06:00 AM
Authors :
B.K. Singh, MD, Neurology, New York Medical College, Valhalla, NY; V. Ramani, MD, Neurology, New York Medical College, Valhalla, NY
RATIONALE: Oxcarbazepine, as an add-on therapy, has been found safe and effective in the patients with partial epilepsy. The objective of this study is to evaluate the safety and efficacy of oxcarbazepine in the patients with developmental disabilities, and refractory epilepsy.
METHODS: We reviewed charts of patients tried on oxcarbazepine as add on therapy due to intractable epilepsy or discontinuation of previous antiepileptic drugs due to adverse effects. There were 26 patients, including 15 males and 11 females.
RESULTS: Dose of oxcarbazepine ranged from 450mg-1800mg/day. Ages ranged from 21 to 65 years (average 41.2). The level of mental retardation: borderline in 2, Mild in 12, moderate in 1, severe in 1 and profound 10 patients. Eight (31%) patients became seizure free and the seizure control improved [gt]50% in 8 (31%) patients. There was no improvement in seizure control in five (19%) patients and seizure frequency increased in one patient. Oxcarbazepine was discontinued in one patient due to marked unsteadiness and we lost follow up in three patients. Ten patients received recommended dose of oxcarbazepine starting at 300mg BID with 300mg/week increment, and 16 patients were given 150 mg BID with 150mg/week increment. Fewer patients (28%) showed unsteadiness with lower dose titration than high dose titration (50%).
CONCLUSIONS: Patients with developmental disabilities and refractory seizures benefited and tolerated oxcarbazepine better with low dose titration.
Disclosure: Consulting - Abbott, Glaxowelcome, Novartis,Ortho-McNeil, Pfizer